In Silico Molecular Docking and Simulation Studies of Protein HBx Involved in the Pathogenesis of Hepatitis B Virus-HBV.
ADMET
HBx protein
MD simulation
binding energy
hepatitis B virus
iGEMDOCK
molecular docking
Journal
Molecules (Basel, Switzerland)
ISSN: 1420-3049
Titre abrégé: Molecules
Pays: Switzerland
ID NLM: 100964009
Informations de publication
Date de publication:
23 Feb 2022
23 Feb 2022
Historique:
received:
28
01
2022
revised:
18
02
2022
accepted:
22
02
2022
entrez:
10
3
2022
pubmed:
11
3
2022
medline:
24
3
2022
Statut:
epublish
Résumé
Current drug discovery involves finding leading drug candidates for further development. New scientific approaches include molecular docking, ADMET studies, and molecular dynamic simulation to determine targets and lead compounds. Hepatitis B is a disease of concern that is a life-threatening liver infection. The protein considered for the study was HBx. The hepatitis B X-interacting protein crystal structure was obtained from the PDB database (PDB ID-3MSH). Twenty ligands were chosen from the PubChem database for further in silico studies. The present study focused on in silico molecular docking studies using iGEMDOCK. The triethylene glycol monoethyl ether derivative showed an optimum binding affinity with the molecular target HBx, with a high negative affinity binding energy of -59.02 kcal/mol. Lipinski's rule of five, Veber, and Ghose were followed in subsequent ADMET studies. Molecular dynamic simulation was performed to confirm the docking studies and to analyze the stability of the structure. In these respects, the triethylene glycol monoethyl ether derivative may be a promising molecule to prepare future hepatitis B drug candidates. Substantial research effort to find a promising drug for hepatitis B is warranted in the future.
Identifiants
pubmed: 35268612
pii: molecules27051513
doi: 10.3390/molecules27051513
pmc: PMC8911951
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Najran University
ID : NU/NRP/MRC/11/2
Références
Lancet. 2015 Oct 17;386(10003):1546-55
pubmed: 26231459
Clin Infect Dis. 2019 Aug 1;69(4):709-712
pubmed: 30605508
CA Cancer J Clin. 2012 Jan-Feb;62(1):10-29
pubmed: 22237781
World J Gastroenterol. 2014 Sep 7;20(33):11630-40
pubmed: 25206269
Adv Drug Deliv Rev. 2001 Mar 1;46(1-3):3-26
pubmed: 11259830
Proteins. 2004 May 1;55(2):288-304
pubmed: 15048822
Nat Biotechnol. 2014 Jan;32(1):40-51
pubmed: 24406927
JAMA. 2006 Jan 4;295(1):65-73
pubmed: 16391218
PLoS One. 2016 Jul 14;11(7):e0158939
pubmed: 27414033
Trends Immunol. 2015 Mar;36(3):124-38
pubmed: 25704559
J Comb Chem. 1999 Jan;1(1):55-68
pubmed: 10746014
J Chem Inf Model. 2012 Nov 26;52(11):3099-105
pubmed: 23092397
Drug Discov Today. 2011 Jan;16(1-2):65-72
pubmed: 21074634
BMC Bioinformatics. 2011 Feb 15;12 Suppl 1:S33
pubmed: 21342564
Comput Biol Med. 2013 Dec;43(12):2063-70
pubmed: 24290922
Cold Spring Harb Perspect Med. 2015 Jul 01;5(7):a021386
pubmed: 26134841
Int J Environ Res Public Health. 2019 Mar 14;16(6):
pubmed: 30875817
J Gen Virol. 2010 Jul;91(Pt 7):1854-64
pubmed: 20219897
Front Immunol. 2021 Aug 12;12:691766
pubmed: 34456908
Lancet. 2016 Sep 10;388(10049):1081-1088
pubmed: 27394647
ChemMedChem. 2016 Jun 6;11(11):1117-21
pubmed: 27218427
Bioinformation. 2014 Sep 30;10(9):562-8
pubmed: 25352723
Nat Rev Drug Discov. 2004 Nov;3(11):935-49
pubmed: 15520816